A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

To have been considered for this study, patients needed to be at least 18 years old and have advanced stomach cancer that tested positive for the HER2 protein. This cancer would have already progressed or returned after previous treatments, including at least one HER2-targeted therapy and certain types of chemotherapy. Additionally, patients would need to be well enough to receive further chemotherapy treatments. The medical team would have checked key body functions, like bone marrow, kidney, and liver health, to ensure they were working adequately.

There were also specific reasons why someone would not have been able to join. For example, if the cancer had spread to the brain and was causing significant symptoms requiring strong medication, or if they had previously received certain experimental drugs that targeted similar pathways as Evorpacept. Patients who had already been treated with Ramucirumab, one of the standard drugs used in this study, would also not have been eligible to participate.

As this study has now stopped, no new patients can take part. However, if it were ongoing, participation would typically involve regular visits to the hospital or clinic. These visits would include physical examinations, blood tests, and scans (like CT scans) to monitor your health and how the treatment is working. You would receive the study medication (Evorpacept) along with standard cancer treatments through infusions (drips). The frequency and duration of these visits would depend on the specific treatment plan, but cancer studies often involve frequent visits initially, gradually becoming less frequent. There would also be follow-up appointments after the main treatment phase to continue monitoring your health over a longer period.